<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606305</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN853-0402</org_study_id>
    <secondary_id>KEYNOTE PN409</secondary_id>
    <nct_id>NCT02606305</nct_id>
  </id_info>
  <brief_title>Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose&#xD;
      Escalation part of the study will assess the safety and tolerability and determine the&#xD;
      maximum tolerated dose (MTD) as the recommended Phase 2 (RP2D) dose for each regimen.&#xD;
      Participants will be assigned to one of the 4 regimens in Dose Escalation phase: Regimen A:&#xD;
      mirvetuximab soravtansine administered with bevacizumab; Regimen B: mirvetuximab soravtansine&#xD;
      administered with carboplatin; Regimen C: mirvetuximab soravtansine administered with&#xD;
      pegylated liposomal doxorubicin; or Regimen D: mirvetuximab soravtansine administered with&#xD;
      pembrolizumab. Dose Expansion of the study will further assess safety, tolerability and&#xD;
      preliminary anti-tumor activity of mirvetuximab soravtansine. A Dose Expansion phase is&#xD;
      planned for Regimen A and Regimen D and will open pending Sponsor decision; participants&#xD;
      enrolled in the Dose Expansion phase will receive study treatment at the MTD or RP2D&#xD;
      determined during Dose Escalation. For Regimen A, participants in the Dose Expansion phase&#xD;
      may be enrolled according to prior exposure to bevacizumab into 3 Dose Expansion Cohorts as&#xD;
      follows: 1) Dose Expansion Cohort 1: bevacizumab naïve; 2) Dose Expansion Cohort 2:&#xD;
      bevacizumab pretreated; and 3) Dose Expansion Cohort 3: one to three prior treatments, one of&#xD;
      which could have been bevacizumab. A triplet Regimen (Regimen E: mirvetuximab soravtansine +&#xD;
      bevacizumab + carboplatin) will be opened to evaluate the safety and tolerability and to&#xD;
      assess any early signs of activity in participants dosed with the combination regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will continue to receive mirvetuximab soravtansine and/or the combination agent&#xD;
      until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, whichever&#xD;
      comes first, or until the Sponsor terminates the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation (Regimens A Through D): Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to approximately 5.3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>From first dose of study drug until first CR or PR (up to approximately 5.3 years)</time_frame>
    <description>Confirmed response includes complete Response (CR) + partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion (Regimens A and D) and Triplet (Regimen E): Number of Participants With TEAEs</measure>
    <time_frame>Baseline up to approximately 5.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response (CR + PR), as Assessed by RECIST Version 1.1</measure>
    <time_frame>From first dose of study drug until first CR or PR (up to approximately 5.3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS); Time From the Date of First Dose Until the Date of PD or Death by Any Cause, as Defined by RECIST Version 1.1</measure>
    <time_frame>From first dose of study drug until the date of PD or death by any cause (up to approximately 5.3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR); the Time From First Objective Response (CR/PR) to the Time of PD Among Those who Have Achieved a PR or CR</measure>
    <time_frame>From the date of first objective response to the time of PD (up to approximately 5.3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gynecologic Cancer Intergroup (GCIG) CA125 Clinical Response</measure>
    <time_frame>Baseline up to approximately 5.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Maximum Plasma Concentration (Cmax) of Intact Mirvetuximab Soravtansine Antibody Drug Conjugate (ADC), Total Antibody, N2'-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-deacetylmaytansine (DM4), and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Area Under the Time-Concentration Curve (AUC) of Intact Mirvetuximab Soravtansine ADC, Total Antibody, DM4, and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Terminal Half-Life (t½) of Intact Mirvetuximab Soravtansine ADC, Total Antibody, DM4, and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clearance (CL) of Intact Mirvetuximab Soravtansine ADC, Total Antibody, DM4, and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Volume of Distribution at Steady State (Vss) of Intact Mirvetuximab Soravtansine ADC, Total Antibody, DM4, and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Time to Reach Cmax (Tmax) of Intact Mirvetuximab Soravtansine ADC, Total Antibody, DM4, and S-methyl DM4</measure>
    <time_frame>Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Bevacizumab, Carboplatin, and Pegylated Liposomal Doxorubicin</measure>
    <time_frame>Bevacizumab and Pegylated Liposomal Doxorubicin: Cycles 1 to 6: Day 1 (pre-infusion, within 10 minutes of EOI); Carboplatin: Cycles 1, 2, 3, 4, 5, 6: Day 1 (pre-infusion, within 10 minutes of EOI; Cycles 1, 3: Days 1 and 2 (6- and 24-hours post-infusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) to Mirvetuximab Soravtansine</measure>
    <time_frame>Baseline up to approximately 5.3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen A (Mirvetuximab soravtansine + Bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (Mirvetuximab soravtansine + Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D (Mirvetuximab soravtansine + Pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab soravtansine</intervention_name>
    <arm_group_label>Regimen A (Mirvetuximab soravtansine + Bevacizumab)</arm_group_label>
    <arm_group_label>Regimen B (Mirvetuximab soravtansine + Carboplatin)</arm_group_label>
    <arm_group_label>Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)</arm_group_label>
    <arm_group_label>Regimen D (Mirvetuximab soravtansine + Pembrolizumab)</arm_group_label>
    <arm_group_label>Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)</arm_group_label>
    <other_name>IMGN853</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Regimen A (Mirvetuximab soravtansine + Bevacizumab)</arm_group_label>
    <arm_group_label>Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Regimen B (Mirvetuximab soravtansine + Carboplatin)</arm_group_label>
    <arm_group_label>Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <arm_group_label>Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Regimen D (Mirvetuximab soravtansine + Pembrolizumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or&#xD;
             fallopian tube cancer&#xD;
&#xD;
          -  FRα positive tumor expression as defined in the protocol&#xD;
&#xD;
          -  Willing to provide an archival tumor tissue block or slides or undergo tumor biopsy.&#xD;
             New tumor biopsy (Cycle 2 Day 8) is required for Regimen D.&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary platinum-refractory disease&#xD;
&#xD;
          -  Diagnosis of clear cell, low grade ovarian cancer or mixed tumors&#xD;
&#xD;
          -  Serious concurrent illness or clinically relevant active infection, including but not&#xD;
             limited to known diagnosis of human immunodeficiency virus (HIV) and hepatitis B or C,&#xD;
             as defined in the protocol&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic therapy in past 2 years (for Regimen D&#xD;
             only)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Male participants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peggy and Charles Stephenson Oklahoma Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial ovarian cancer</keyword>
  <keyword>Fallopian tube cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <keyword>IMGN853</keyword>
  <keyword>ADC</keyword>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>ImmunoGen</keyword>
  <keyword>Antibody</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Folate receptor alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

